Angle A $400M financing cleared after the data washout, leaving the registrational path as the rebound hook.
TYRA sold off hard after initial SURF302 data, but the underlying readout still showed a 79% overall response rate with manageable safety and the company is moving dabogratinib toward registrational development [#27, #36]. Today’s 14% rebound came alongside pricing of a $400M offering, which can reset the financing overhang after the post-data drawdown rather than leave dilution risk unresolved [#3, #10].
Catalyst Near-term re-rating depends on investors reassessing dabogratinib’s registrational path after the offering is absorbed.
AI Status:TYRA closed after three days with a +0.96% realized gain as the post-offering rebound faded before registrational-path rerating took hold.
The position entered at 25.50 and exited via our exit signal with about +0.96% realized PnL after three trading days, well below the +2.51% peak gain and after a drawdown that reached roughly -5.12% intraday. The financing overhang had cleared on the thesis, but price action stayed structurally weak with EMA20 below SMA50 and SMA200 despite a close slightly above the 20-day EMA. At exit, RSI sat at 50 with MACD histogram positive and rolling up while weekly RSI remained sub-50 and below its average.